IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2313
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$295M
Mihael H. Polymeropoulos
Vanda Pharmaceuticals Inc. focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders. Its products under development include Fanapt (iloperidone) and Tradipitant (VLY-686) The company markets its products in the United States, Europe, and Israel.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$VNDA Vanda Pharmaceuticals Inc. | 48 | 51 | 22 | 69 | - | - | -25.9% | -17.3% | 95.0% | -58.5% | -40.5% | 11.5% | 0.0% | 49.0x | $295M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Vanda Pharmaceuticals Inc. (VNDA) receives a "Reduce" rating with a composite score of 48.1/100. It ranks #2313 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for VNDA.
View All RatingsROE proxy -25.9% (sector -1.9%)
GM 95% vs sector 44%, OM -58% vs sector 3%
Capital turnover N/A, R&D intensity 50.6%
Rev growth 11%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Vanda Pharmaceuticals Inc. (VNDA) as a Reduce with a composite score of 48.1/100 at a current price of $8.32. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Vanda Pharmaceuticals Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.1/100 places it at rank #2313 in our full universe.
The near-term outlook is constructive, with revenue growing at 11% and momentum in the 69th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Medium
Poor
Fair Value
Gross margins of 95% signal strong pricing power.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Vanda Pharmaceuticals Inc. represents a reduce based on multi-factor quantitative performance.
Vanda Pharmaceuticals Inc. receives a Reduce rating from our analysis, with a composite score of 48.1/100 and 2 out of 5 stars, ranking #2313 out of 7,333 stocks. VNDA's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, VNDA shows adequate but unremarkable business quality. The company reports a return on equity of -25.9% (sector avg: -1.9%), gross margins of 95.0% (sector avg: 44.1%), net margins of -40.5% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
VNDA registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.04x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 43/100, VNDA exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 11.5% vs. a sector average of 6.7% and a return on assets of -17.3% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
VNDA demonstrates moderate momentum with a score of 69/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 11.5% year-over-year, while a beta of 0.49 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 58/100, VNDA exhibits average financial resilience. Key stability metrics include a beta of 0.49 and a debt-to-equity ratio of 49.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Vanda Pharmaceuticals Inc.'s short interest score of 34/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 49.00x), micro-cap liquidity risk. At $295M (micro-cap), VNDA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Vanda Pharmaceuticals Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2313 of 7,333 overall (68th percentile). Key comparisons include ROE of -25.9% trailing the -1.9% sector median and operating margins of -58.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While VNDA currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (22) would have the largest impact on the composite score.
ROE 1261% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 116% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2430% BELOW SECTOR MEDIAN
U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with several individual stocks showing significant moves based on company announcements and FDA approvals.
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
Vanda Pharmaceuticals recently received U.S. FDA approval for BYSANTI (milsaperidone) tablets, a new atypical antipsychotic for acute manic or mixed episodes in bipolar I disorder and for schizophrenia in adults, with U.S. commercial launch targeted for the third quarter of 2026 and marketing protection expected into 2044. BYSANTI’s status as a new chemical entity that rapidly converts to iloperidone, aligning with Fanapt’s established safety profile while offering dual active molecules,...
Vanda shares rise after FDA approves Bysanti for bipolar I and schizophrenia, with launch planned for 2026.
FDA's approval of Bysanti boosts Vanda's portfolio, with potential to treat bipolar disorder, schizophrenia, and major depressive disorder.
Above 50MA
37.18%
Net New Highs
+51081